The drive to domestically replace high-end medical imaging equipment is unstoppable.

Release time:

2025-03-01

Medical imaging technology employs physical methods to acquire biological information, enabling the visualization of health status and serving as a core technology that drives the advancement of clinical disease early warning, diagnosis, and treatment.

The drive to domestically replace high-end medical imaging equipment is unstoppable.

Medical imaging technology leverages physical principles to acquire biological information, enabling the visualization of health status. It serves as a core technology driving advances in clinical disease early warning, diagnosis, and treatment, and is one of the most interdisciplinary and technically demanding sectors within high-end equipment manufacturing. As such, it epitomizes a nation’s level of high-tech development and is often hailed as the “pearl of high-end equipment manufacturing.”

　　In recent years, as China’s overall R&D capabilities in medical devices have steadily improved, the medical imaging equipment industry has experienced rapid growth, achieving breakthroughs on both the technological innovation front and in market applications, thereby gradually breaking the long-standing monopoly of imported equipment. However, in the high-end equipment segment, challenges remain, including heavy reliance on imported core components and low domestic market penetration for domestically produced devices. All stakeholders in the industry should therefore pay close attention to the opportunities presented by emerging technological advancements and work collaboratively to support the high-quality development of the high-end medical imaging equipment sector.

Related News

Overview of Bioanalytical Methods for Cell Therapy Products

Cell and gene therapy (CGT) can be broadly classified, based on product format, into ex vivo gene therapy and in vivo gene therapy.

2026-04-03

Bioanalytical Strategies for CGT Products: Selected Developments and Validation of qPCR/ddPCR Methodologies

With the rapid development of cell and gene therapy (CGT), dozens of CGT products have now been approved for market launch worldwide.

2026-04-03

Pharmaceutical and Biotechnology Industry Watch: Innovative Drugs and Medical Devices Fuel Structured Market Performance; AI in Healthcare Opens New Growth Opportunities

During the third week of February 2025, the pharmaceutical and biotechnology sector continued to exhibit structural divergence. Over the week, the pharmaceutical and biotechnology index rose by 1.88%, outperforming both the CSI 300 Index and the Shanghai Composite Index, ranking ninth in terms of sector performance.

2025-03-01

Pharmaceutical and Biotechnology Industry Watch: AI-Driven Healthcare Applications Accelerate Deployment; Breakthroughs in Payment-Policy for Innovative Drugs

Recently, the pharmaceutical and biotechnology sector has exhibited a pronounced structural market trend, driven by the deep integration of AI technologies with healthcare applications, which is spurring industry upgrades. At the same time, policy support for innovative drugs continues to strengthen, creating multiple favorable factors for the sector.

2025-03-01

With the concerted support of 17 departments, the latest policies for the biopharmaceutical industry in the Jiangsu Pilot Free Trade Zone have been unveiled!

Recently, the “Policy Measures for Coordinated Support from Relevant Provincial Departments for the Open and Innovative Development of the Biopharmaceutical Industry in the China (Jiangsu) Pilot Free Trade Zone” (hereinafter referred to as the “Policy Measures”) were officially released!

2025-03-01

Medical Device Industry Development Report: Significant Market Potential in Countries Along the Belt and Road

Recently, the “Medical Device Blue Book: Report on the Development of China’s Medical Device Industry (2018),” jointly released in Beijing by the China Association for Pharmaceutical Regulatory Research and the Social Sciences Academic Press, stated that since the Belt and Road Initiative was proposed in 2013, demand for Chinese medical device products has increased among countries along the Belt and Road.

2025-03-01

Share